Identification of a
prostate inhibitory substance in a pollen extract.
Habib FK, Ross M, Lewenstein A, Zhang X, Jaton JC.
University Department of Surgery, Western General Hospital, Edinburgh,
Prostate. 1995 Mar;26(3):133-9.
Recently, much attention has focused on the treatment of BPH with the pollen
extract. The present investigation was designed to identify the active
component in this agent which might be responsible for the symptomatic
BPH as previously reported. Sequential purification of the active component
present in the pollen extract was carried out by a combination of dialysis,
filtration, and reverse phase chromatography. To monitor the biological
each of the purified fractions, a biological assay employing the human
cancer cell line DU145 was undertaken. While we have identified a number of
constituent components in the pollen extract, only one fraction designated
(FV-7) maintained a strong inhibitory effect on the growth of DU145 cells.
inhibition was time- and dose-dependent, and the concentrations of FV-7
to reduce the cell numbers by 50% (IC50) after 2 days of exposure was 5
micrograms/ml. FV-7 was also inhibitory towards the primary culture of
stroma and epithelial cells, with the stroma/fibroblast showing greater
towards the HPLC-purified component. However, it should be noted that this
inhibitory activity measured in the primary culture cells was only achieved
higher concentrations of FV-7. Preliminary characterization of the active
ingredient identified FV-7 as DIBOA which is a cyclic hydroxamic acid. FV-7
and DIBOA induce similar inhibitory effects on the growth of DU145 cells.
PMID: 7899151 [PubMed - indexed for MEDLINE]